Konstantin H. Dragnev

Also affiliated with Dartmouth–Hitchcock Medical Center, Dartmouth Psychiatric Research Center, Dartmouth Hospital, Dartmouth Cancer Center

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 15 papers. Top paper: “Phase II Study of Docetaxel and Trametinib in Patients with KRAS Mutation Positive Recurrent Non–Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042)”.

Phase II Study of Docetaxel and Trametinib in Patients with KRAS Mutation Positive Recurrent Non–Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042)

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-3947

N/A

0.862DataRank · unranked

21 citations

Jieling Miao, Jonathan W. Riess, James Moon, Philip C. Mack, Gregory J. Gerstner +10 more

Protein-altering germline mutations implicate novel genes related to lung cancer development

Nature Communications(2020)10.1038/s41467-020-15905-6

N/A

0.587DataRank · unranked

49 citations

Semanti Mukherjee, Maria Teresa Landi, Yohan Bossé, Philippe Joubert, Dakai Zhu +95 more

Lung-MAP Next-Generation Sequencing Analysis of Advanced Squamous Cell Lung Cancers (SWOG S1400)

Journal of Thoracic Oncology(2024)10.1016/j.jtho.2024.07.024

N/A

0.326DataRank · unranked

5 citations

Xing Hua, Michael C. Wu, Khaled Tolba, Saiama N. Waqar, Konstantin H. Dragnev +10 more

Major hurdles to the use of tyrosine kinase inhibitors in clinical prevention/interception studies: Do preclinical studies with EGFR inhibitors suggest approaches to overcome some of the limitations

Frontiers in Cell and Developmental Biology(2023)10.3389/fcell.2023.1170444

N/A

0.241DataRank · unranked

4 citations

Christo Philip C. Dragnev, Ronald A. Lubet, Konstantin H. Dragnev

Phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non-small cell lung cancer previously treated with a checkpoint inhibitor: Toxicity update (Lung-MAP non-matched sub-study S1800A).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.9075

N/A

0.104DataRank · unranked

1 citations

Mary W. Redman, Konstantin H. Dragnev, Liza C. Villaruz, Bryan A. Faller, Tareq Al Baghdadi +7 more

Data from Uncovering Growth-Suppressive MicroRNAs in Lung Cancer

(2023)10.1158/1078-0432.c.6517807.v1

N/A

0DataRank · unranked

0 citations

Lorenzo F. Sempere, Fabrizio Galimberti, Sarah J. Freemantle, Candice C. Black, Konstantin H. Dragnev +11 more

The effect of ctDNA tumor fraction (TF) on overall survival and concordance between tissue genomics and ctDNA in Lung-MAP.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.9035

N/A

0DataRank · unranked

0 citations

Mary W. Redman, David Kozono, Sam Callis, Hanna Tukachinsky, Khaled Tolba +14 more

Chemical genetic screens reveal defective lysosomal trafficking as synthetic lethal with NF1 loss

Journal of Cell Science(2024)10.1242/jcs.262343

N/A

0DataRank · unranked

5 citations

Andrew V. Grassetti, Robert J. Allaway, Matthew Wood, Helen W. Hou, India R. Burdon Dasbach +7 more

Efficacy and Safety of Olomorasib in Combination With Pembrolizumab in Treatment of Patients With KRAS G12C-Mutant Advanced NSCLC

Journal of Thoracic Oncology(2025)10.1016/j.jtho.2025.11.018

N/A

0DataRank · unranked

5 citations

Natraj Reddy Ammakkanavar, Antoine Hollebecque, Dae Ho Lee, Takafumi Koyama, Philippe A. Cassier +20 more

Association of DPYD rs4294451, plasma uracil concentration, and sex with 5-fluorouracil exposure in patients with gastrointestinal cancer

Cancer Chemotherapy and Pharmacology(2025)10.1007/s00280-025-04851-z

N/A

0DataRank · unranked

1 citations

Dylan B. Ness, Kathryn Cunningham Hourdequin, Gregory H. Ripple, Manik Amin, Sierra Lord-Halvorson +8 more

A pragmatic, single-arm clinical trial of a dose modification algorithm for preventing cytopenia-related delays during FOLFOX chemotherapy

Supportive Care in Cancer(2025)10.1007/s00520-025-09784-0

N/A

0DataRank · unranked

0 citations

Tor D. Tosteson, Kathryn Cunningham Hourdequin, Gregory H. Ripple, Alexander D. Fuld, Konstantin H. Dragnev +9 more

Impact of neuroimaging in the pretreatment evaluation of early stage non-small cell lung cancer

Heliyon(2020)10.1016/j.heliyon.2020.e04319

N/A

0DataRank · unranked

6 citations

Christopher Del Prete, Jonathan A.D. Farrell, Konstantin H. Dragnev, Gregory A. Russo, Graham Atkins +3 more

Prioritizing Measures That Matter Within a Person-Centered Oncology Learning Health System

JNCI Cancer Spectrum(2022)10.1093/jncics/pkac037

N/A

0DataRank · unranked

6 citations

Alice Kennedy, Kathryn B Kirkland, Konstantin H. Dragnev, Steven D. Leach, Madge E. Buus‐Frank +81 more

Representativeness of patients enrolled in the Lung Cancer Master Protocol (Lung-MAP).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.6543

N/A

0DataRank · unranked

0 citations

Joseph M. Unger, Qian Lü, Katherine Minichiello, Roy S. Herbst, David R. Gandara +14 more

Data from Uncovering Growth-Suppressive MicroRNAs in Lung Cancer

(2023)10.1158/1078-0432.c.6517807

N/A

0DataRank · unranked

0 citations

Lorenzo F. Sempere, Fabrizio Galimberti, Sarah J. Freemantle, Candice C. Black, Konstantin H. Dragnev +11 more